Rick Simpson Oil (RSO) in Saint Clair County, Illinois: The Complete Evidence-Based Guide by OilWell Cannabis

If you’re reading this from Belleville, East St. Louis, O’Fallon, Granite City, Collinsville, or anywhere across Saint Clair County, you’ve likely heard the term “RSO” floating through conversations about cannabis and serious health conditions. Maybe a neighbor mentioned it while discussing cancer treatment at Memorial Hospital. Perhaps a veteran friend from Scott Air Force Base brought it up for PTSD and chronic pain. Or you’re a caregiver in Alton looking for options when conventional medicine falls short. Wherever you are in our Metro East community, you deserve honest, complete information about Rick Simpson Oil — not hype, not promises, just the facts grounded in what the science actually says.

We wrote this guide because Saint Clair County residents deserve better than the fragmented, often misleading information about RSO circulating online. Whether you’re exploring options for cancer support, chronic pain that won’t respond to opioids, debilitating PTSD, or simply want to understand what RSO really is, this is the comprehensive resource we wish had existed when we started our journey.

Understanding Rick Simpson Oil: From Nova Scotia to Saint Clair County

Who Was Rick Simpson (And Why His Story Still Matters Here)

Rick Simpson wasn’t a doctor, scientist, or medical researcher. He was a power engineer from Amherst, Nova Scotia — a blue-collar tradesman whose introduction to concentrated cannabis oil came through personal suffering, not laboratory study. In 1997, while working at a hospital in Moncton, Simpson fell from scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and post-concussion symptoms that conventional medicine couldn’t resolve. The medications he was prescribed either failed to help or made things worse. When he asked his doctor about cannabis, the request was refused — a scenario that still resonates with many Saint Clair County patients who’ve been dismissed when asking about alternative options.

Simpson’s interest deepened after learning about a 1974 NIH-funded study at the Medical College of Virginia, where THC reportedly slowed tumor growth in mice. That study — intended to demonstrate harm — became foundational to his advocacy, even though its findings were never replicated in controlled human trials.

The pivotal moment came in 2003. Simpson reported that three bumps on his arm were diagnosed as basal cell carcinoma. Rather than pursuing conventional treatment, he applied concentrated cannabis oil directly to the lesions. According to his account, they disappeared within four days. Important context: No independent medical verification, biopsy confirmation, or clinical follow-up has ever been published in any peer-reviewed source. This was personal testimony, not medical evidence — but it was historically significant as the catalyst for a global movement.

The Traditional RSO Protocol: What Simpson Actually Recommended

After his 2003 experience, Simpson committed himself to producing and distributing concentrated cannabis oil, giving it away for free to cancer patients and others in his community. He claimed to help people with cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and more — conditions that affect thousands of Saint Clair County residents today.

His core protocol was specific: 60 grams of oil over approximately 90 days.

The Titration Schedule Simpson Used

• Week 1: Start with a dose the size of half a grain of dry rice (roughly 10-15mg) taken three times daily. Total daily intake: 30-45mg.
• Weeks 2-5: Double the dose approximately every four days to build THC tolerance gradually. Target: reach approximately 1 gram (1,000mg) per day by week 5.
• Weeks 5-12: Maintain 1 gram per day divided into three roughly equal doses (333mg each) until all 60 grams are consumed.

Administration Methods Simpson Recommended

• Oral (primary): Place dose under tongue (sublingual) or swallow. Considered most important for systemic absorption and internal cancers.
• Topical (secondary): Apply directly to lesions for skin cancers, combined with oral dosing.
• Inhalation (not primary): Simpson acknowledged smoking or vaporizing for immediate symptom relief but maintained oral route was essential for sustained, high-dose exposure.

Critical Context for Saint Clair County Readers Evaluating This Protocol

This protocol was designed around crude, single-strain extract with no standardized potency. Several vital considerations apply:

• No controlled trial validation. Zero published randomized controlled trials, cohort studies, or well-documented case series support this specific 60g/90-day protocol for any cancer type or condition.
• Very high THC exposure. At peak dosing (1g/day of high-THC oil), patients consumed approximately 600-900mg of delta-9 THC daily — far exceeding anything studied clinically. For perspective, FDA-approved dronabinol is typically dosed at 2.5-20mg/day.
• Real risks at these doses. Consuming 600-900mg of THC daily carries serious risks: severe intoxication, anxiety, panic, tachycardia, hypotension, cannabis use disorder, and potential mental health impacts. Saint Clair County residents with families, jobs, and responsibilities cannot function on these doses.
• No standardization. Every batch varied based on plant genetics, growing conditions, solvent purity, and extraction technique. No lab testing, no cannabinoid quantification, no contaminant screening.

Traditional RSO Product: What It Actually Was

Traditional RSO is defined by Simpson’s method, not lab specifications:

• Source material: Single high-THC indica strain, no strain standardization
• Extraction solvent: Naphtha (petroleum-based) or 99% isopropyl alcohol — neither food-grade
• Process: Bucket, solvent, agitate, filter, rice cooker evaporation, syringes
• Appearance: Nearly black, thick, tar-like, with possible solvent-residual smell
• Cannabinoid profile: THC-dominant (60-90% estimated), fully decarboxylated, minor cannabinoids at natural ratios
• Terpene content: Minimal to none — destroyed by solvent and heat
• Standardization: None. Every batch different. No COA, no testing.
• Residual solvent risk: Naphtha may contain benzene, toluene, other carcinogens. Incomplete purging difficult to verify without lab testing.

Simpson’s Claims vs. The Evidence: What Saint Clair County Needs to Know

Simpson claimed RSO could cure cancer and many diseases. Let’s be honest about what the evidence actually shows:

What Simpson was not: Not a scientist, physician, or researcher. No formal medical training. No published trials. No peer review. His evidence was personal experience and testimonials.

What preclinical literature shows: In vitro and animal studies demonstrate THC and CBD can induce apoptosis, inhibit proliferation, and reduce angiogenesis in certain cancer cell lines. Animal models show some tumor-growth inhibition. Scientifically interesting, but not human proof.

What preclinical literature does NOT show: These findings have NOT translated into proven human cancer cures. No human clinical trial has demonstrated RSO or any cannabis oil cures cancer. The gap between lab results and human outcomes is vast.

Institutional positions:

• National Cancer Institute (NCI): Acknowledges cannabinoid anticancer research but does NOT endorse cannabis as cancer treatment.
• FDA: Has NOT approved any cannabis plant product for cancer. Only Epidiolex (CBD) for seizures and synthetic THC analogues for chemo nausea/AIDS wasting.
• Health Canada: Never approved RSO for cancer.
• NCCIH: Strongest evidence is for rare epilepsies, chemo nausea, and HIV/AIDS appetite — not cancer cure.

What Simpson got right: He drew attention to cannabinoids as serious biomedical research when the world ignored it. He helped create conditions for today’s legal cannabis industry. The term “RSO” remains the most recognized name for full-spectrum cannabis extract.

What he overstated: Cure claims exceeded evidence. Encouraging patients to use RSO instead of proven cancer therapies carries genuine harm potential. Delayed treatment for treatable cancers is a documented concern. For Saint Clair County residents facing serious diagnoses at cancer centers in Belleville or seeking treatment in St. Louis, this is not a decision to make without oncologist involvement.

The Evolution: Why Saint Clair County Deserves Better Than Traditional RSO

The term “RSO” is now used loosely across the legal cannabis industry. Many products labeled RSO bear little resemblance to what Simpson made. In Illinois dispensaries, RSO can refer to almost any full-spectrum extract in a syringe, regardless of extraction method, cannabinoid profile, or quality.

Simpson himself criticized commercial products that use the RSO name while departing from his method. He believed medicine should be free and DIY. The modern industry commercialized what he distributed freely. Whether that’s improvement (quality control, testing) or betrayal (profit, gatekeeping) depends on perspective, but what matters for Saint Clair County is this: modern RSO has evolved substantially, and those changes directly benefit you.

Traditional RSO vs. Modern Formulated RSO

Dimension	Traditional RSO	OilWell Formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None — every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not available or performed	Full panel testing (potency, terpenes, pesticides, heavy metals, residual solvents, microbial)
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content (553 mg/mL)
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No — fully decarboxylated by heat	Yes — THCa included as separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why Our Formulas Diverge from Traditional RSO

Our formulations are not traditional RSO. They are informed by the tradition but depart from it in deliberate, evidence-motivated ways:

Multi-cannabinoid approach. Traditional RSO relied on whatever single strain the maker grew. Our formulas intentionally include seven cannabinoids — CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC — because the entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited.

Terpene preservation and addition. Traditional RSO had essentially no terpene content due to solvent and heat destruction. We include live terpenes at 5 percent with a specific seven-terpene profile — limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene — because terpene bioactivity is plausible and supported at the preclinical level, even if human clinical confirmation remains developing.

THCa as a separate ingredient. Traditional RSO fully decarboxylated everything. Our sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because the THCa literature suggests potentially relevant non-psychoactive bioactivity that is lost when THCa converts to THC.

Reduced delta-9 THC dominance. Traditional RSO was overwhelmingly delta-9 THC (60-90% of total cannabinoids). Our sublingual formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg and distributing the remaining cannabinoid content across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), and CBC (750 mg). This reflects the broader cannabinoid research landscape rather than a single-compound dominance model.

Product format innovation. Simpson envisioned only one format: oral oil from a syringe. We offer both a 30 mL sublingual oil and a 1-gram vape cartridge, each with format-specific formulation acknowledging that different delivery routes have different pharmacokinetic profiles.

Our Story: How a Paralyzed Dog Named Bentley Changed Everything

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. But our story doesn’t start in a boardroom — it starts in McAllen, Texas, right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. Colin grew up there, learning to hustle in an environment where violence was routine, best friends were killed or imprisoned, and by sixteen, he had to leave home for good.

Despite the dangers, Colin didn’t fall into selling harder substances. He focused on cannabis, seeing it as a safer, more beneficial alternative. He learned the plant intimately in the traditional cannabis world pre-legalization, then transitioned to legal business. He later became a formally trained software engineer, doing custom development work for Baylor College of Medicine — one of the most prestigious medical institutions in the Texas Medical Center. That combination of deep cannabis plant knowledge plus medical-grade technical precision defines everything we do.

Bentley’s Miracle: The Foundation of Our Mission

Our company’s origin story begins with a dog named Bentley. Bentley was more than a pet — he was family, the companion who stood by Colin through the toughest border years. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said pain medications would destroy his internal organs, causing more suffering. The choice was painful prolonged decline or immediate mercy killing.

Giving up on Bentley was not an option. In a desperate search for alternatives, Colin stumbled upon CBD through a question that changed everything. Jessica, a rescue worker, asked: “You’ve moved how many tons of weed and you’ve never heard of CBD?” That exposed a blind spot that became our mission.

Colin created CBD golden paste — a specialized cannabinoid formula for pets. It was not a cure, but it was hope. And that hope delivered what veterinary medicine said was impossible: Bentley got up, walked over, and brought Colin his ball to play. From paralyzed and facing euthanasia to fetching his ball. This was not placebo — dogs don’t respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced. Neurodegeneration led to understanding CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led to CBC’s role in neurogenesis. Glaucoma led to THC’s CB1 agonism for intraocular pressure. Crippling arthritis led to multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene simultaneously.

Single cannabinoids weren’t enough. Bentley’s evolving conditions required multi-cannabinoid synergy. That decade of real-world formulation testing on a patient Colin loved more than anything became the foundation of our RSO formula — the same formula now available to you in Saint Clair County.

From Personal Crisis to Community Mission

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey — notoriously difficult and dangerous — using the cannabinoid knowledge developed keeping Bentley alive. The Peace Gummies formula that became an OilWell product was created during midnight experiments while fighting through benzo withdrawal. He personally uses the vape form for insomnia and severe PTSD. This is not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

Over time, doctors began using our formulas for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. We’ve developed formulations for vegans, diabetics, and those with specific health needs. Our focus has always been making cannabis accessible and effective for everyone.

ABC13 Houston: Seven Features, Four Years, One Expert

Between September 2019 and April 2023, ABC13 Houston (KTRK) — the ABC affiliate serving America’s fourth-largest city — featured Colin and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different reporters sought us out across those years. No other Houston cannabis operator appears with that frequency or breadth.

When ABC13 needed to explain a new cannabis product, it called Colin. When state agencies reversed Delta-8 legality overnight, it called Colin. When President Biden announced marijuana pardons and the station needed someone who had personally lived with a cannabis conviction to provide context, it called Colin. When they wanted to tell the story of a growing industry on 4/20, it was Colin’s hemp field and voice that anchored the report.

From our September 2019 debut to our April 2023 “Renaissance” framing, our media trajectory mirrors the trajectory of legal cannabis itself. For Saint Clair County residents evaluating our credibility, this sustained mainstream media validation from a major-market ABC affiliate demonstrates that our expertise is independently verified — not purchased, but earned through consistent, honest engagement.

The Philosophy That Defines Us

Our approach to RSO is built on four core principles that evolve Simpson’s original vision:

1. Accessibility over gatekeeping. No medical card required. Anyone age 21+ can purchase. We ship nationwide to Illinois and internationally to jurisdictions where hemp-derived products are legal. Simpson believed medicine should be accessible to everyone; we built a product and distribution model that makes that legally possible for Saint Clair County residents.

2. Patient-controlled potency. THCa is sold in its acidic, non-psychoactive form. YOU decide whether to use it raw for non-psychoactive benefits or decarboxylate it into delta-9 THC for full psychoactive potency. Simpson believed patients should control their medicine; we engineered a product that puts that control in your hands through chemistry, not rhetoric.

3. Open-source formulas. We publish our complete formulas publicly — every cannabinoid, every milligram, every percentage — so anyone who cannot afford our products can source ingredients and make their own. We gave away the CBD golden paste recipe that saved Bentley years before publishing our RSO formulas. This isn’t marketing; it’s foundational behavior.

4. Evidence-informed, not evidence-overstating. The science section of this document represents our commitment to honest education about what research actually says. We distinguish between what’s well-supported, what’s emerging, and what’s overstated. This is the “best possible version” Colin promised in his first ABC13 interview — not hype, but real information so you can make informed decisions for yourself and your loved ones in Saint Clair County.

Farm Bill Compliance and Illinois Legal Framework

The 2018 Farm Bill legalized hemp and hemp-derived products containing less than 0.3% delta-9 THC by dry weight at the federal level. This legal framework is the foundation of our product design and enables us to serve Saint Clair County residents.

Our RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle — 3 milligrams per milliliter — well under the 0.3% threshold. All cannabinoids are hemp-derived. The product is legal under federal law and in Illinois.

THCa: The Legal Distinction That Gives You Control

THCa (tetrahydrocannabinolic acid) is the acidic, non-psychoactive precursor to delta-9 THC. It is NOT itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at point of sale because it hasn’t been converted to delta-9 THC.

The practical significance for Saint Clair County residents is substantial. You can decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F (125°C) for 45-60 minutes in an oven-safe glass container. This converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC in our formula, this yields approximately 1,405 milligrams of total delta-9 THC — giving the product psychoactive potency comparable to traditional illegal RSO, entirely at YOUR discretion after purchase.

You can also transfer a controlled portion from the original bottle into a second oven-safe container, decarboxylating only what you intend to use while preserving the remainder in raw THCa form.

This means the same product can function as:

• Non-psychoactive anti-inflammatory (used raw) for daytime use without impairment
• Full-potency psychoactive cannabinoid medicine (after home decarboxylation) for nighttime or when psychoactivity is desired

The conversion chemistry is straightforward: THCa has a molecular weight of 358.47 g/mol. The conversion ratio is approximately 1 mg THCa = 0.877 mg delta-9 THC after decarboxylation, reflecting the loss of a CO₂ molecule.

Important legal notice for Illinois residents: THCa converts to delta-9 THC when heated. Customers are responsible for understanding and complying with Illinois law regarding cannabinoid products. We ship with full documentation, Certificates of Analysis, and receipts. International customers accept all customs and legal risk. Illinois residents should be aware that while our products are federally compliant, they should verify local regulations regarding possession and use of decarboxylated products.

Complete Open-Source Formulas: Full Transparency for Saint Clair County

We publish our complete RSO formulas publicly because you deserve to know exactly what you’re putting in your body. If you cannot afford our professionally manufactured products, you can source the individual cannabinoid distillates and isolates and make your own version. This is our commitment to accessibility for every Saint Clair County resident, regardless of economic circumstances.

RSO Sublingual Oil Formula

Cannabinoid	Amount
CBD	4,500 mg
CBG	3,000 mg
Delta-8 THC	6,000 mg
THCa	1,500 mg
Delta-9 THC	90 mg
CBN	750 mg
CBC	750 mg
Total Cannabinoids	16,590 mg

• Live Terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Carrier: Organic MCT oil
• Format: 30 mL bottle with graduated dropper (0.1 mL increments)
• Potency: 553 mg total cannabinoids per mL
• Onset: 15-45 minutes (sublingual)
• Duration: 4-6 hours
• Bioavailability: 13-19%
• Approximate doses per bottle: 40-60 depending on serving size

RSO Vape Cartridge Formula

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%+
• Format: 1-gram 510-thread cartridge (universal battery compatibility)
• Total cannabinoids: 900+ mg
• Onset: 1-2 minutes (fastest delivery method)
• Duration: 2-4 hours
• Bioavailability: 10-35%
• Note: THCa auto-decarboxylates at vaping temperature (400-450°F)

Terpene Profile (Both Products)

Our seven-terpene profile is identical across both formats, delivering consistent aroma, flavor, and potential entourage benefits:

• Limonene: Citrus-bright notes, potential mood elevation
• Myrcene: Earthy foundation, often associated with relaxation
• Caryophyllene (β-caryophyllene): Pepper/spice character, selective CB2 receptor agonist
• Pinene: Forest-fresh aroma, potential clarity enhancement
• Linalool: Floral, lavender-like, calming properties
• Humulene: Earthy, woody, anti-inflammatory potential
• Terpinolene: Piney, fruity, sparkling complexity

For Saint Clair County residents familiar with Midwestern forests and gardens, these terpenes create a sensory experience that connects botanical tradition with modern cannabinoid science.

How to Use Our RSO in Saint Clair County: Sublingual vs. Vape

We offer two formats because different situations require different delivery methods. Here’s how to choose what’s right for your Saint Clair County lifestyle:

When to Use Each Format

Use Case	Recommended Format	Why It Works for Saint Clair County
Fast relief (acute pain, nausea, panic attack)	Vape	1-2 minute onset – crucial when you need immediate support before a doctor’s appointment in Belleville or during a PTSD episode
Sustained relief (chronic pain, sleep maintenance)	Sublingual	4-6 hour duration provides all-day or all-night coverage for conditions requiring consistent management
Maximum bioavailability	Sublingual	13-19% absorption gets more cannabinoids into your system – cost-effective for Saint Clair County residents on fixed incomes
Portability/discretion	Vape	Compact, no measuring required – fits in a pocket for use at work in Granite City or while visiting family in Collinsville
Precise dosing control	Sublingual	Graduated dropper allows 0.1 mL increments – perfect for titrating to your exact therapeutic window
Daytime non-psychoactive use	Sublingual (raw)	THCa stays inactive, zero impairment – ideal for working at the refineries, driving through Metro East, or caring for family
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC provides therapeutic psychoactivity when you want it, without lingering into next morning

Decarboxylation: Your Potency Decision

Option 1: Raw (No Heat) – All 1,500 mg stays as THCa, completely non-psychoactive. Perfect for Saint Clair County residents who need anti-inflammatory benefits during work hours, parents who must stay alert for their children, or anyone who wants therapeutic effects without impairment. The THCa literature suggests potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism.

Option 2: Fully Activated (Home Decarb) – Heat at 260°F for 45-60 minutes. Converts 1,500 mg THCa to ~1,315 mg delta-9 THC. Combined with existing 90 mg delta-9 THC, yields ~1,405 mg total delta-9 THC. This delivers psychoactive potency comparable to traditional illegal RSO, 100% legally, because decarboxylation occurs at your discretion after purchase. You can decarb the entire bottle or transfer a portion to a separate container and decarb only what you need.

Option 3: Vape (Auto-Decarb) – Each puff at 400-450°F instantly converts THCa to delta-9 THC. Fastest relief for breakthrough symptoms.

Condition-Specific Usage Context for Saint Clair County Residents

Important Disclaimer: The following contexts are informed by cannabinoid research cited in our science section. They are NOT medical prescriptions, NOT FDA-approved treatment protocols, and NOT substitutes for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, take medications, are pregnant or nursing, or have health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-Related Nausea and Appetite Support

For Saint Clair County residents undergoing treatment at Memorial Hospital Belleville, St. Elizabeth’s, or traveling to Siteman Cancer Center in St. Louis:

• Pre-chemo: 0.5-1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2-3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0-2.0 mL sublingual before bed (delivers 25-50 mg CBN)

Evidence context: Delta-8 THC antiemetic properties, delta-9 THC’s established role in chemo nausea management, CBD’s anxiolytic buffering effects.

Chronic Pain (Fibromyalgia, Arthritis, Neuropathy, Industrial Injuries)

For Saint Clair County’s working-class communities dealing with pain from manufacturing, industrial work, or aging:

• Daytime (functional): 0.3-0.5 mL raw sublingual — anti-inflammatory cannabinoid exposure without psychoactive impairment
• Nighttime (restorative): 0.5-1.0 mL decarboxylated sublingual — combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset

Evidence context: CBD’s analgesic pathways, delta-9 THC pain modulation, beta-caryophyllene’s CB2 agonism (particularly relevant for inflammatory pain), THCa’s COX-2 inhibition.

Sleep Support (Insomnia, Disrupted Sleep Architecture)

For Saint Clair County residents whose sleep is disrupted by chronic pain, PTSD, or shift work:

• Before bed: 1.0-2.0 mL sublingual
• At 2.0 mL: Delivers 50 mg CBN — the dosage level investigated in 2024 sleep literature showing reduced sleep disturbance
• At 1.0 mL: Delivers 25 mg CBN — above the 20 mg threshold associated with improved sleep initiation

Evidence context: CBN sleep studies, cannabis and sleep architecture research.

Anxiety, Stress, and PTSD

For Saint Clair County veterans, trauma survivors, and those dealing with the pressures of economic uncertainty:

• Daytime functional relief: 0.3 mL raw sublingual — CBD and CBG address anxiety pathways without impairment
• Nighttime: 1.0 mL sublingual — full cannabinoid profile including CBN for sleep

Evidence context: CBD’s anxiolytic effects, CBG’s pharmacological profile, limonene’s anxiolytic potential in entourage contexts.

Delivery and Global Accessibility for Saint Clair County

While we operate same-day delivery in Houston, we proudly serve Saint Clair County residents through nationwide shipping that brings our products directly to your doorstep in Belleville, O’Fallon, Granite City, and throughout the Metro East region.

Shipping to Saint Clair County, Illinois

• Carrier: USPS Priority Mail (2-3 business days), FedEx Ground, or UPS Ground (3-5 business days)
• Packaging: Discreet with no cannabis branding visible
• Tracking: Provided for all orders
• Temperature-stable packaging: Ensures product integrity during summer shipments across Illinois
• Signature-required option: Available for added security

Illinois Cannabis Law Context

Illinois legalized recreational cannabis in January 2020. However, access can be limited in certain areas of Saint Clair County, and medical card requirements can create barriers. Our products are Farm Bill compliant, requiring no medical card — only age verification (21+). This makes our RSO accessible to Saint Clair County residents who may not qualify for Illinois medical programs or prefer not to navigate that system.

International Shipping

We ship internationally and have delivered to multiple countries across continents. The THCa legal framework makes this possible: because our products contain less than 0.3% delta-9 THC at point of sale, they meet hemp definitions and are shippable to jurisdictions with compatible laws. International packages include full documentation, Certificates of Analysis, and customs receipts. Customers accept all customs and legal responsibility.

Accessibility Commitment

Whether you’re in downtown Belleville, a rural area near New Douglas, or anywhere in Saint Clair County, you have the same access to our products as someone in Houston. We don’t believe geography should determine who gets therapeutic options.

Competitive Comparison: Why OilWell Stands Apart

We present factual comparisons based on publicly available specifications. These help Saint Clair County residents understand what makes our approach different without attacking competitors.

OilWell RSO vs. Typical Dispensary RSO (Illinois Market)

Dimension	Typical Illinois Dispensary RSO	OilWell RSO
Cannabinoid profile	THC-only or THC-dominant	7 cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
CBG content	0-50 mg (if any)	3,000 mg
CBN content	0-100 mg (if any)	750 mg
CBC content	Rarely included	750 mg
Patient-controlled potency	No — always psychoactive	Yes — THCa non-psychoactive until YOU heat it
Access requirements	Medical card or recreational dispensary visit	Age 21+ only, ships directly to your Saint Clair County home
Terpene content	Often minimal or unspecified	Live terpenes at 5% with defined 7-terpene profile
Lab testing	Yes (Illinois requirement)	Yes — full panel with COAs available
Total cannabinoids	Typically 500-1,000 mg per syringe	16,590 mg per bottle (30 mL)

OilWell RSO vs. Hemp CBD RSO Products

Dimension	Typical Hemp CBD RSO	OilWell RSO
Total cannabinoids	1,000-2,000 mg	16,590 mg
CBD content	~90% of total	4,500 mg (27% of total)
Delta-8 THC	0 mg	6,000 mg
THCa (convertible)	Minimal	1,500 mg
Psychoactive option	No meaningful effect	Yes — via THCa decarboxylation
Price per mg cannabinoid	Higher cost	More economical

Key Advantages for Saint Clair County Residents

No travel required. You don’t need to drive to Collinsville or wait in line at a dispensary. We ship directly to your Saint Clair County address.

No medical card needed. While Illinois medical programs exist, our products are accessible to any adult 21+ in Saint Clair County, whether you qualify for medical status or not.

More comprehensive formulation. Seven cannabinoids vs. one or two means broader therapeutic potential for complex conditions common in Saint Clair County (chronic pain, PTSD, cancer support).

Patient control. You decide when and if psychoactivity occurs — crucial for working families, veterans, and anyone needing functional daytime relief.

Transparency. We publish our exact formulas. Most companies don’t. You deserve to know precisely what you’re buying.

The Science Behind Every Cannabinoid in Your RSO

We hold ourselves to the same evidence standards we apply to the broader field. Here’s what the research actually says about each compound in our formula:

CBD (Cannabidiol) — 4,500 mg

The most evidence-developed nonintoxicating cannabinoid in our formula. Strongest human evidence: seizure disorders (Epidiolex FDA approval). Emerging evidence: A 2024 systematic review of 316 participants across eight studies showed statistically significant anxiolytic effects, though authors stress the clinical sample remains limited. Pain research: A 2024 systematic review found promising but heterogeneous results, with trial quality limiting broad analgesic claims. Sleep: 2023 review found methodologically weak literature, mostly subjective measures. Safety: 2023 meta-analysis identified real signals for liver enzyme elevation and possible drug-induced liver injury, especially relevant for concentrated oral products and polypharmacy settings. Bottom line: Strong evidence in specific indications, not broad wellness panacea.

CBG (Cannabigerol) — 3,000 mg

Evidence profile: Mostly review-level and preclinical; human evidence remains sparse. Pharmacology: CBG is the biosynthetic precursor to major cannabinoids, interacting with cannabinoid receptors, alpha-2 adrenoceptors, and 5-HT1A pathways — mechanistically interesting but not clinically established. Research areas: Reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, and antibacterial activity, but primarily as pharmacology-led hypotheses. Caution: CBG is commercially sold while the evidence base remains thin — claims often outrun science. Bottom line: Promising minor cannabinoid with limited clinical validation, not yet proven therapeutic.

Delta-8 THC — 6,000 mg

Evidence profile: Pharmacologically relevant and psychoactive, but much less clinically characterized than delta-9 THC. Comparative pharmacology: A 2022 review concluded delta-8 and delta-9 THC have broadly similar pharmacokinetic and pharmacodynamic behavior. Delta-8 is a partial CB1 agonist with cannabimimetic activity, but appears less potent than delta-9, likely due to weaker CB1 affinity. Public health: A 2023 scoping review found the evidence base dominated by animal studies, product chemistry, and use reports, with noted adverse consequences and regulatory concerns. Manufacturing: Commercial delta-8 interest is tied to greater stability and easier synthesis relative to naturally scarce plant levels, raising product-byproduct and lab-testing questions. Bottom line: Psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and manufacturing-quality uncertainties.

THCa (Tetrahydrocannabinolic Acid) — 1,500 mg

Evidence profile: Important chemically and formulation-wise, but low on direct human therapeutic evidence. THCa is the acidic precursor of THC and may represent a large share of THC-related content in raw plant material. Key issue: THCa decarboxylates into THC during heating and can change during storage and processing. Psychoactivity: THCa itself does not produce psychoactive effects associated with THC, but the distinction only holds if the molecule stays acidic and isn’t substantially decarboxylated. Research status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but not equivalent to established human outcomes. Bottom line: Highly relevant precursor whose interpretation depends heavily on route, temperature, processing, and storage — any claim must account for possible conversion into THC.

Delta-9 THC — 90 mg (3 mg/mL)

Evidence profile: Strongest human evidence of the psychoactive cannabinoids listed, but also clearest adverse-effect burden. Institutionally supported uses: NCCIH identifies relevance to chemotherapy-related nausea/vomiting, appetite/weight loss in HIV/AIDS, and some multiple sclerosis/pain outcomes, while stressing many other uses remain uncertain. Pain evidence: A 2022 systematic review found high-THC products or comparable THC:CBD ratios may provide short-term pain benefit but increase dizziness, sedation, nausea, and treatment discontinuation due to adverse events. Pharmacokinetics: Inhaled THC produces effects within seconds-minutes, peaks in 15-30 minutes, and tapers over hours; oral THC has later onset, later peak, and longer duration. Mental health risk: A 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis/schizophrenia outcomes and cannabis use disorder, with concerning signals for anxiety and depression in nontherapeutic settings. Broader safety: Anxiety/panic at high doses, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, and vape-related lung-injury concerns. Bottom line: Legitimate therapeutic relevance in some settings, but carries the clearest intoxication, psychiatric, and dose-related safety liabilities.

CBN (Cannabinol) — 750 mg

Evidence profile: Weak human evidence; marketing has moved ahead of the data. Commonly marketed for sleep and sedation, but clinical support is far thinner than the market suggests. Best sleep evidence review: A 2021 narrative review screened 99 human-study abstracts and reviewed eight full-text articles, finding NO clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims. Broader sleep literature: 2024 updated review concluded cannabinoid sleep research still doesn’t match real-world use scale, with need for better-designed, adequately powered trials. Chemical context: THC can degrade toward CBN under certain conditions, explaining why CBN is often discussed in aging/oxidized cannabis contexts. Bottom line: CBN is one of the clearest examples where cultural reputation is stronger than current clinical evidence base.

CBC (Cannabichromene) — 750 mg

Evidence profile: Emerging, intriguing, and overwhelmingly preclinical or review-based. Pharmacology: 2024 focused review argues CBC has distinct pharmacodynamics, pharmacokinetics, and receptor behavior relative to better-known cannabinoids, highlighting antinociceptive, antibacterial, and anti-seizure areas as especially interesting research targets. Older literature: Review literature reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, and possible neurobiological/antiproliferative relevance, but these are not strong evidence for patient-facing claims. Safety caveat: 2024 CBC review explicitly notes over-the-counter CBC products are already being sold despite little evidence establishing clinical efficacy or safety. Bottom line: Scientifically credible minor cannabinoid deserving more research, not already-validated clinical active.

Understanding Terpenes: The Entourage Effect Explained

Our seven-terpene profile is included at 5% concentration in both products because terpene bioactivity is plausible and supported at preclinical level, even though robust human clinical proof of cannabis-specific entourage effects remains limited. Here’s what we know about each terpene in your RSO:

Limonene

Citrus-bright notes. 2021 review describes multifunctional properties: antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory. However, most claims come from nonhuman/non-cannabis literature. Safety note: Limonene oxidation products (hydroperoxides) are clinically relevant contact allergens.

Myrcene

Earthy foundation. 2021 review describes anxiolytic, antioxidant, anti-inflammatory, analgesic properties but explicitly states human studies are lacking. Claims about myrcene causing “couch-lock” sedation are stronger than current human evidence supports.

Caryophyllene (β-caryophyllene)

Pepper/spice character. Most mechanistically interesting terpene – 2021 review describes it as selective CB2 receptor agonist, making it especially relevant pharmacologically rather than just aromatic. Research themes include anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective effects. Still mostly preclinical.

Pinene

Forest-fresh aroma. 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, neuroprotective signals justifying future study, but emphasized well-designed clinical trials are lacking.

Linalool

Floral, lavender-like. Substantial preclinical interest, limited direct clinical confirmation. 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological/psychiatric contexts. Oxidized linalool hydroperoxides are recognized allergens.

Humulene

Earthy, woody. 2024 scoping review analyzed 340 articles, finding broad preclinical evidence for anti-inflammatory effects, with some rodent work suggesting cannabimimetic properties via CB1 and adenosine A2a pathways. Valuable for hypothesis generation, not yet consistent human efficacy.

Terpinolene

Piney, fruity, sparkling. Least clinically characterized terpene in our profile. 2021 systematic review screened 2,449 records, included 57 studies, concluding terpinolene has reported biological effects but evidence base dominated by in silico, in vitro, and animal studies.

Research Limits and Interpretation: What Saint Clair County Should Know

The evidence base is highly uneven. CBD and delta-9 THC support the most detailed human-facing statements; the rest require more caution. Five critical interpretation rules:

1. Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data are not interchangeable. One common error is letting evidence from one category stand in for another.

2. Minor cannabinoids and terpenes are commercially interesting because they’re underexplored, but that also means claims around them often become inflated.

3. Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, and route-dependent pharmacokinetics all materially affect real-world interpretation.

4. For THCa, chemistry is destiny: Storage and heating can change actual exposure profile by converting acidic cannabinoids into neutral cannabinoids like THC.

5. Entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific.

Common Overstatements to Avoid (And What We Actually Know)

Overstatement: CBN is a clinically proven sleep cannabinoid.
More accurate: Specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base identified.

Overstatement: Myrcene is a proven human sedative that reliably explains couch-lock.
More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof for this common claim is limited.

Overstatement: Terpenes in general have proven entourage effects in patients.
More accurate: Entourage hypotheses are influential, but robust clinical proof remains limited and highly compound-specific.

Overstatement: THCa is always non-psychoactive.
More accurate: THCa itself is not THC, but heating and processing can convert THCa into THC, changing effective exposure.

Overstatement: Delta-8 THC is safe because it’s hemp-derived.
More accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns.

Practical Takeaways for Saint Clair County

• Most evidence-developed actives: CBD and delta-9 THC
• Delta-8 THC: Not trivial or purely mild – psychoactive cannabinoid with less robust safety/efficacy characterization than delta-9 THC
• THCa: Meaningfully changes with processing – should not be interpreted the same in raw vs. heated formats
• CBG, CBN, CBC: Scientifically credible but clinically immature compared to CBD and THC
• Terpenes: Likely relevant to aroma, flavor, and potential biologic activity, but compound-specific therapeutic claims should be conservative

The CBD Golden Paste Recipe That Started It All

Before we published RSO formulas, we gave away the recipe that saved Bentley. We share it here for any Saint Clair County pet owner facing a similar crisis:

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1-2 teaspoons freshly ground black pepper (critical for absorption)
• CBD oil (dosage depends on pet size/needs; consult veterinarian)

Instructions:

1. Mix turmeric and water in saucepan over low heat, stirring continuously until thick paste forms (7-10 minutes)
2. Add coconut oil and black pepper, stir until thoroughly mixed
3. Allow to cool, transfer to jar with lid, refrigerate up to 2 weeks
4. Add CBD oil to paste before serving, adjusting dosage based on weight/health needs

Serving: Mix small amount with pet’s food once or twice daily. Monitor changes. Consult veterinarian before starting any supplement regimen.

This recipe demonstrates our open-source pattern is foundational behavior, not marketing strategy. We gave away what saved Bentley before we ever sold RSO.

References

Cannabinoid and Terpene Research

1. National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH. Accessed March 2026. Available at: https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know
2. Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023;359:114238.
3. Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol CBD in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;339:116049.
4. Cásedas G, Yarza-Sancho M, López V. Cannabidiol CBD: A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals Basel. 2024;17(11):1438.
5. Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in the management of insomnia: A systematic review. Cannabis Cannabinoid Res. 2023;8(2):213-229.
6. Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023;293(6):724-752.
7. Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212.
8. Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol CBG: A comprehensive review of its molecular mechanisms and therapeutic potential. Molecules. 2024;29(22):5471.
9. Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol delta8 THC: Comparative pharmacology with delta9 THC. Br J Pharmacol. 2022;179(15):3915-3933.
10. LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta-8 tetrahydrocannabinol: A scoping review and commentary. Addiction. 2023;118(6):1011-1028.
11. Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249.
12. Moreno-Sanz G. Can You Pass the Acid Test? Critical review and novel therapeutic perspectives of delta9-Tetrahydrocannabinolic Acid A. Cannabis Cannabinoid Res. 2016;1(1):124-130.
13. McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis-based products for chronic pain: A systematic review. Ann Intern Med. 2022;175(8):1143-1153.
14. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360.
15. Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High-concentration delta-9-tetrahydrocannabinol cannabis products and mental health outcomes: A systematic review. Ann Intern Med. 2025;178(10):1429-1440.
16. Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366-371.
17. Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis and CBD to sleep: An updated review. Curr Psychiatry Rep. 2024;26(12):712-727.
18. Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup-Konsavage WM. The potential of cannabichromene as a therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206-213.
19. Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm. 2021;71(3):355-364.
20. André R, Gomes AP, Pereira-Leite C, Marques-da-Costa A, Monteiro Rodrigues L, Sassano M, Rijo P, Costa MDC. The entourage effect in cannabis medicinal products: A comprehensive review. Pharmaceuticals Basel. 2024;17(11):1543.
21. Anandakumar P, Kamaraj S, Vanitha MK. D-limonene: A multifunctional compound with potent therapeutic effects. J Food Biochem. 2021;45(1):e13566.
22. Ogueta IA, Brared Christensson J, Giménez-Arnau E, Brans R, Wilkinson M, Stingeni L, Foti C, Aerts O, Svedman C, Gonçalo M, Giménez-Arnau A. Limonene and linalool hydroperoxides review: Pros and cons for routine patch testing. Contact Dermatitis. 2022;87(1):1-12.
23. Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene: What are the potential health benefits of this flavouring and aroma agent? Front Nutr. 2021;8:699666.
24. Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of beta-caryophyllene, a dietary cannabinoid. Biomed Pharmacother. 2021;140:111639.
25. Weston-Green K, Clunas H, Jimenez Naranjo C. A review of the potential use of pinene and linalool as terpene-based medicines for brain health: Discovering novel therapeutics in the flavours and fragrances of cannabis. Front Psychiatry. 2021;12:583211.
26. Dos Santos ÉRQ, Maia JGS, Fontes-Júnior EA, do Socorro Ferraz Maia C. Linalool as a therapeutic and medicinal tool in depression treatment: A review. Curr Neuropharmacol. 2022;20(6):1073-1092.
27. Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. The clinical translation of alpha-humulene: A scoping review. Planta Med. 2024;90(9):664-674.
28. Menezes IO, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS, Coutinho HDM, Ribeiro-Filho J, de Menezes IRA. Biological properties of terpinolene evidenced by in silico, in vitro and in vivo studies: A systematic review. Phytomedicine. 2021;93:153768.
29. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364.

Rick Simpson Source Materials

RS1. Simpson R. Phoenix Tears: The Rick Simpson Story. Simpson RamaDur LLC; 2012.
RS2. Laurette C, director. Run From The Cure: The Rick Simpson Story . 2005. Distributed via phoenixtears.ca.
RS3. Simpson R. Instructions and dosing information published on phoenixtears.ca. Multiple dates. Accessed March 2026.
RS4. Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436-444.
RS5. Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197-203.
RS6. National Cancer Institute. Cannabis and Cannabinoids (PDQ) — Health Professional Version. NIH/NCI. Updated 2024. Available at: https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq

Legal Disclaimers and Safety Information for Saint Clair County Residents

• Age requirement: 21+ only
• FDA disclaimer: These products have not been evaluated by the Food and Drug Administration. They are not intended to diagnose, treat, cure, or prevent any disease.
• Medical consultation: Always consult a qualified healthcare provider before use, especially if you have a medical condition, take medications, are pregnant or nursing, or have health concerns.
• Impairment warning: May cause drowsiness or impairment. Do not operate vehicles, machinery, or heavy equipment while under the influence of psychoactive cannabinoids.
• Product variability: Individual results may vary. Effects depend on body weight, metabolism, tolerance, concurrent medications, and other factors.
• Customer responsibility: Customers are responsible for verifying legality in their jurisdiction and accepting all customs and legal risk for international orders.
• Void where prohibited: Products are void where prohibited by law.

OilWell Cannabis Contact Information

• Phone: (832) 416-2816
• Email: [email protected]
• Website: https://oilwellcbd.com/
• Address: 810 Richmond Ave, Houston, TX 77006 (Montrose neighborhood)
• Hours: Monday-Thursday 10 AM-7 PM, Friday-Saturday 10 AM-10 PM, Sunday 10 AM-4 PM
• Instagram: @oilwellcbd

For Saint Clair County residents ready to experience the difference that evidence-informed, patient-controlled, multi-cannabinoid RSO can make — whether for cancer support, chronic pain, PTSD, sleep, or overall wellness — we invite you to order today. Your journey with cannabinoids should be guided by honest information, not hype. That’s the OilWell promise, from Houston to the heart of Illinois.